Home › Ovarian Epithelial Carcinoma › Montana › Billings
Ovarian Epithelial Carcinoma clinical trials in Billings, MT
3 studies for Ovarian Epithelial Carcinoma are looking for participants at sites in and around Billings (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
RecruitingPhase 3
- Research Site, Billings
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
RecruitingPhase 3
- Research Site, Billings
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RecruitingPhase 3
- St. Vincent Gynecologic Oncology, Billings
Ovarian Epithelial Carcinoma trials in other cities
- Durham, NC8 studies
- Boston, MA8 studies
- San Diego, CA7 studies
- New York City, NY7 studies
- Chicago, IL7 studies
- Baltimore, MD6 studies
- Philadelphia, PA6 studies
- Cleveland, OH6 studies
- Houston, TX6 studies
- Portland, OR5 studies
- Minneapolis, MN5 studies
- Salt Lake City, UT5 studies
Other studies in Billings
- Non-Small Cell Lung Cancer17 studies
- Prostate Cancer15 studies
- Lung Cancer13 studies
- Breast Cancer10 studies
- Ovarian Cancer9 studies
- Melanoma7 studies
- Chronic Lymphocytic Leukemia7 studies
- Acute Myeloid Leukemia7 studies
- Bladder Cancer6 studies
- Colon Cancer6 studies
- Colorectal Cancer6 studies
- Rectal Cancer5 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.